Market Overview:
The global organ transplantation immunosuppressive drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of organ failures, rising awareness about organ donation and transplantation, and technological advancements in the field of organ transplantation. The global market for organ transplantation immunosuppressive drugs is segmented on the basis of type into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, antibodies, and steroids. On the basis of application, it is segmented into kidney transplants, bone marrow transplants liver transplants heart transplants lungs transplants and others (including pancreas and small bowel). Geographically speaking North America dominates this market followed by Europe Asia Pacific Latin America Middle East & Africa respectively.
Product Definition:
An organ transplantation immunosuppressive drug is a medication that is prescribed to help prevent the body from rejecting a transplanted organ. These drugs are important because they help keep the recipient's immune system from attacking the new organ as if it were a foreign invader.
Calcineurin Inhibitors:
Calcineurin inhibitors are immunosuppressive drugs that prevent the immune system from responding to normal body processes. They do not affect the body's natural ability to create new antibodies, but they do block some of the actions of calcineurin when it is activated by interleukins or other signals.
Antiproliferative Agents:
Antiproliferative agents are used in transplantation to reduce the risk of cancer or tumor recurrence. They are also used as immunosuppressive drugs to prevent rejection of the transplanted organ by the recipient. Antiproliferative agents can be further categorized into two types: non-specific and specific.
Application Insights:
The kidney transplant segment dominated the global organ transplantation immunosuppressive drugs market in 2017, owing to a rise in the number of patients requiring a kidney transplant. According to data published by U.S. National Library of Medicine National Institutes of Health, around 120,000 people are on waiting lists for a kidney transplant across the globe. An increase in chronic diseases such as diabetes and obesity has led to an increased demand for dialysis machines which further increases the risk of infection due to surgical procedures performed during dialysis treatment which is expected to drive growth over the forecast period.
Regional Analysis:
North America dominated the global organ transplantation immunosuppressive drugs market in 2017. The presence of well-developed healthcare infrastructure, high adoption rate of innovative therapies and increasing prevalence of chronic kidney diseases & heart failure are some factors attributing to its large share. In addition, increasing number of donors is also expected to contribute towards the growth over the forecast period. According to AABB International, there were a total 699 kidney transplants performed in U.S from 2012 to 2016; this number increased by 17% compared with 2011 and 9% compared with 2010 (Kidney Disease Outcomes Report).
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure levels coupled with growing patient awareness regarding organ donation activities across countries such as India & China & Japan etcetera In addition, government initiatives for creating awareness about these programs are also contributing towards its rapid development phase Moreover, rapidly improving economic conditions in emerging countries such as India.
Growth Factors:
- Increasing incidence of organ failures and organ transplantations is expected to drive the demand for immunosuppressive drugs over the forecast period.
- Rising awareness about benefits of immunosuppressive drugs is anticipated to propel the market growth.
- Technological advancements in drug delivery systems are likely to provide lucrative opportunities for market players.
- Growing number of clinical trials for new immunosuppressive drugs is projected to boost the demand for these products in near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Organ Transplantation Immunosuppressive Drug Market Research Report
By Type
Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitors, Antibodies, Steroids
By Application
Kidney Transplant, Bone Marrow Transplant, Liver Transplant, Heart Transplant, Lungs Transplant, Others Transplant
By Companies
AbbVie, Allergan Plc, Astellas Pharma, Bristol-Myers Squibb Company, Roche, GlaxoSmithKline plc, Novartis AG, Pfizer, Sanofi S.A., Veloxis Pharmaceuticals A/S
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
151
Number of Tables & Figures
106
Customization Available
Yes, the report can be customized as per your need.
Global Organ Transplantation Immunosuppressive Drug Market Report Segments:
The global Organ Transplantation Immunosuppressive Drug market is segmented on the basis of:
Types
Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitors, Antibodies, Steroids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Kidney Transplant, Bone Marrow Transplant, Liver Transplant, Heart Transplant, Lungs Transplant, Others Transplant
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Allergan Plc
- Astellas Pharma
- Bristol-Myers Squibb Company
- Roche
- GlaxoSmithKline plc
- Novartis AG
- Pfizer
- Sanofi S.A.
- Veloxis Pharmaceuticals A/S
Highlights of The Organ Transplantation Immunosuppressive Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Calcineurin Inhibitors
- Antiproliferative Agents
- mTOR Inhibitors
- Antibodies
- Steroids
- By Application:
- Kidney Transplant
- Bone Marrow Transplant
- Liver Transplant
- Heart Transplant
- Lungs Transplant
- Others Transplant
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Organ Transplantation Immunosuppressive Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Organ transplantation immunosuppressive drugs are medications used to prevent organ rejection after a transplant. These drugs can help the body to accept the new organ more easily and may prolong the time that a person can receive an organ transplant.
Some of the major companies in the organ transplantation immunosuppressive drug market are AbbVie, Allergan Plc, Astellas Pharma, Bristol-Myers Squibb Company, Roche, GlaxoSmithKline plc, Novartis AG, Pfizer, Sanofi S.A., Veloxis Pharmaceuticals A/S.
The organ transplantation immunosuppressive drug market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Organ Transplantation Immunosuppressive Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Organ Transplantation Immunosuppressive Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Organ Transplantation Immunosuppressive Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Organ Transplantation Immunosuppressive Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Organ Transplantation Immunosuppressive Drug Market Size & Forecast, 2020-2028
4.5.1 Organ Transplantation Immunosuppressive Drug Market Size and Y-o-Y Growth
4.5.2 Organ Transplantation Immunosuppressive Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Calcineurin Inhibitors
5.2.2 Antiproliferative Agents
5.2.3 mTOR Inhibitors
5.2.4 Antibodies
5.2.5 Steroids
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Kidney Transplant
6.2.2 Bone Marrow Transplant
6.2.3 Liver Transplant
6.2.4 Heart Transplant
6.2.5 Lungs Transplant
6.2.6 Others Transplant
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Organ Transplantation Immunosuppressive Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Organ Transplantation Immunosuppressive Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Calcineurin Inhibitors
9.6.2 Antiproliferative Agents
9.6.3 mTOR Inhibitors
9.6.4 Antibodies
9.6.5 Steroids
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Kidney Transplant
9.10.2 Bone Marrow Transplant
9.10.3 Liver Transplant
9.10.4 Heart Transplant
9.10.5 Lungs Transplant
9.10.6 Others Transplant
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Calcineurin Inhibitors
10.6.2 Antiproliferative Agents
10.6.3 mTOR Inhibitors
10.6.4 Antibodies
10.6.5 Steroids
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Kidney Transplant
10.10.2 Bone Marrow Transplant
10.10.3 Liver Transplant
10.10.4 Heart Transplant
10.10.5 Lungs Transplant
10.10.6 Others Transplant
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Calcineurin Inhibitors
11.6.2 Antiproliferative Agents
11.6.3 mTOR Inhibitors
11.6.4 Antibodies
11.6.5 Steroids
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Kidney Transplant
11.10.2 Bone Marrow Transplant
11.10.3 Liver Transplant
11.10.4 Heart Transplant
11.10.5 Lungs Transplant
11.10.6 Others Transplant
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Calcineurin Inhibitors
12.6.2 Antiproliferative Agents
12.6.3 mTOR Inhibitors
12.6.4 Antibodies
12.6.5 Steroids
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Kidney Transplant
12.10.2 Bone Marrow Transplant
12.10.3 Liver Transplant
12.10.4 Heart Transplant
12.10.5 Lungs Transplant
12.10.6 Others Transplant
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Calcineurin Inhibitors
13.6.2 Antiproliferative Agents
13.6.3 mTOR Inhibitors
13.6.4 Antibodies
13.6.5 Steroids
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Kidney Transplant
13.10.2 Bone Marrow Transplant
13.10.3 Liver Transplant
13.10.4 Heart Transplant
13.10.5 Lungs Transplant
13.10.6 Others Transplant
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Organ Transplantation Immunosuppressive Drug Market: Competitive Dashboard
14.2 Global Organ Transplantation Immunosuppressive Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Allergan Plc
14.3.3 Astellas Pharma
14.3.4 Bristol-Myers Squibb Company
14.3.5 Roche
14.3.6 GlaxoSmithKline plc
14.3.7 Novartis AG
14.3.8 Pfizer
14.3.9 Sanofi S.A.
14.3.10 Veloxis Pharmaceuticals A/S
